Therapeutic Indications:

For improvement of post-prandial hyperglycemia in diabetic mellitus only when diet and/or exercise or oral hypoglycemic drug or insulin preparation in addition to diet and/or exercise do not result in adequate glycemic control.

Posology and Method of Administration Usual Adult Dose:

Voglibose dispersible Tablets are orally administered in a single dose of 0.2 mg three times daily just before each meal. If the effect is not sufficient enough, the single dose may be increased up to 0.3 mg, under close observation of the course of disease.

USE IN SPECIAL POPULATIONS

Paediatrics The safety of Voglibose dispersible Tablets in children has not been established (no clinical experience). NOT FOR CHILDREN USE Geriatrics Since the elderly have a physiological hypo function in general, the administration of Voglibose dispersible Tablets should be initiated at a lower dose (e.g. single dose of 0.1 mg).

Fertility, Pregnancy and Lactation:

Pregnancy

Voglibose dispersible Tablets should be administered to pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk [The safety of this drug In pregnant women has not been established].

Lactation

It is desirable to avoid the administration of this drug to nursing mothers. However, if the administration is indispensable, nursing should be discontinued.